Related Experiment Video
Updated: Jul 11, 2026
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Reoperative sentinel lymph node biopsy in patients with locally recurrent breast cancer
Julie L Barone1, Sheldon M Feldman, Alison Estabrook
1Continuum Cancer Centers of New York, Appel-Venet Comprehensive Breast Service, Phillips Ambulatory Care Center, Beth Israel Medical Center, 10 Union Square E., Ste 4E, New York, NY 10003, USA.
Background:
Sentinel lymph node biopsy (SLNB) is considered a standard of care in the staging of breast cancer. The objective was to examine our experience with reoperative SLNB.
Methods:
We identified 19 patients in our breast cancer database who had a SLNB in the reoperative setting. All 19 patients had undergone previous breast-conserving surgery with either an axillary lymph node dissection or an SLNB. The reoperative sentinel lymph node (SLN) was identified using blue dye, radioisotope, or both.
Results:
The SLN was identified in 84% of the reoperative cases. Of these successful cases, both blue dye and radioisotope were used in five cases, and radioisotope alone was used in 11 cases. Radioisotope identified the SLN in the 100% of successful SLNB cases (P = .0003). There were 3 unsuccessful cases in which blue dye and radioisotope failed to identify the sentinel node.
Conclusions:
Reoperative SLNB after previous axillary surgery is technically feasible.
